Evidence map›Paper›PMID 41572827›Full record

ArticleImmunotherapy

Multi-omics insights into gut microbial dysbiosis and metabolic alterations in immune checkpoint inhibitor-induced thrombocytopenia.

Bei Xu, Peng Liu, Na Yan, Tao Wang, Ling Liu, Yunfeng Cheng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunotherapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bei XuDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Peng LiuDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.
Na YanKey Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Dian Diagnostics Group Co. Ltd, Hangzhou, Zhejiang, China.
Tao WangKey Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Dian Diagnostics Group Co. Ltd, Hangzhou, Zhejiang, China.
Ling LiuKey Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Dian Diagnostics Group Co. Ltd, Hangzhou, Zhejiang, China.
Yunfeng ChengDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune checkpoint inhibitors-induced thrombocytopenia (ICIs-TCP) is a rare immune-related adverse events (irAEs). The physiological changes underlying ICIs-TCP remain incompletely elucidated.

methodsWe performed multi-omics analysis (gut microbiome, plasma metabolomics/proteomics) comparing microbial/metabolic alterations in cancer patients with (

resultsPatients with ICIs-TCP exhibited distinct gut microbiota profiles, with an increased abundance of

conclusionThe depletion of arginine and associated metabolic disruptions are associated with ICIs-TCP and may represent a potential therapeutic target for mitigating TCP risk in patients receiving ICIs.

Indexed as

DysbiosisGastrointestinal MicrobiomeImmune Checkpoint InhibitorsNeoplasmsThrombocytopeniaAgedFemaleHumansMaleMetabolomicsMiddle AgedMultiomicsProteomicsImmune Checkpoint Inhibitorsgut microbiotaICIsirAEsmulti-omicsthrombocytopenia

Identifiers

PMID41572827
PMCPMC12952268

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.